CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.
'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.'
This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor.
The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company ContactInspira Technologies – Media RelationsEmail: info@inspirao2.comPhone: +972-9-9664485
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Yorkton Equity Group Inc. Announces Normal Course Issuer Bid for Common Shares
EDMONTON, ALBERTA - June 6, 2025 (NEWMEDIAWIRE) - Yorkton Equity Group Inc. ("Yorkton" or the "Company") (TSX.V: YEG) announces its has received TSX Venture Exchange (the "Exchange") approval to commence a normal course issuer bid (the "NCIB") through the facilities of the Exchange to repurchase, for cancellation, up to an aggregate of 5,634,028 common shares of the Company ("Common Shares"), representing approximately 5% of the outstanding Common Shares. The funds used to repurchase the Common Shares under the NCIB will only come from cash provided by operating activities of the Company. The NCIB is expected to commence on June 6, 2025 and will terminate upon the earliest of (i) the Company purchasing 5,634,028 Common Shares, (ii) the Company providing notice of termination of the NCIB, and (iii) on June 5, 2026. The Company believes that, from time to time, the market price of its common shares does not adequately reflect the Company's underlying value and future prospects such that having the ability to purchase the Company's common shares represents an appropriate use of the Company's financial resources and will enhance shareholder value. The Company has engaged Independent Trading Group (ITG), Inc. to act as its broker for the NCIB (the "Broker"). The NCIB will be made through the facilities of the Exchange and the purchase and payment for the Common Shares will be made from the Company's cash that has been generated by its operating activities, at the market price of the Common Shares at the time of acquisition (plus brokerage fees, if any, charged by the Broker). All Common Shares purchased by the Company under the NCIB will be cancelled. To the Company's knowledge, none of the directors, senior officers or insiders of the Company, or any associate of such person, or any associate or affiliate of the Company, has any present intention to sell any securities to the Company during the NCIB. A copy of the Form 5G Notice of Intention to make a Normal Course Issuer Bid filed by the Company with the Exchange in respect of the NCIB can be obtained from the Company upon request without charge. About Yorkton Yorkton Equity Group Inc. is a growth-oriented real estate investment company committed to providing shareholders with growing assets through accretive acquisitions, organic growth, and the active management of multi-family rental properties with significant upside potential. Our current geographical focus is in Alberta and British Columbia with diversified and growing economies, and strong population in-migration. Our business objectives are to achieve growing Net Operating Income ("NOI") and asset values in our multi-family rental property portfolio in strategic markets across Western Canada. The management team at Yorkton Equity Group Inc. has well over 30 years of prior real estate experience in acquiring and managing rental assets. Further information about Yorkton is available on the Company's website at and the SEDAR+ website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information on Yorkton, please contact: Ben Lui, CEOTelephone: (780) 409-8228Email: investors@ Forward-looking information This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of Yorkton. Forward-looking information is based on certain key expectations and assumptions made by the management of Yorkton. Although Yorkton believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Yorkton can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Yorkton disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirement.
Business Insider
2 hours ago
- Business Insider
iOThree receives Nasdaq notification regarding minimum bid price deficiency
iOThree (IOTR) Limited announced that it has received a written notification from the Nasdaq Stock Market LLC on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'IOTR'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until December 1, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. Confident Investing Starts Here:
Yahoo
3 hours ago
- Yahoo
‘They are in shock': Indian students fear Trump has ended their American dream
For weeks, Subash Devatwal's phone has not stopped ringing. Some of the calls have been from distressed students, at other times it is their panicked parents, but all have the same question – is their dream of studying in the US still possible? Devatwal runs an education consultancy in Ahmedabad, the main city in the Indian state of Gujarat. It is one of thousands of such organisations that exist across the country, helping Indian students achieve what many consider to be the ultimate symbol of success: getting into an American university. It has long been a booming business for Devatwal. Families in India will often invest their entire life savings to send their children to study in the US and last year there were more than 330,000 Indians enrolled at American universities, more than any other foreign nationality, overtaking Chinese students in numbers for the first time in years. But this year the situation looks drastically different. As Donald Trump's administration has taken aim at international students – first implementing draconian screening measures over political views and then last week ordering all US embassies globally to indefinitely pause all student visa interviews – many Indian students and their families have been left in limbo. Trump's unilateral decision to block Harvard University from admitting international students, which was later blocked by the courts, also caused widespread panic and stoked fears that foreign students at other universities could get caught in the president's crosshairs. 'The students are in shock. Most of them spend several years preparing to study in the US,' said Devatwal. He said many of his clients were now hesitant to pursue a US degree, given the high levels of turmoil and uncertainty following the Trump administration's new policies. Indian students can expect to pay between $40,000 to $80,000 (£29,500 to £59,000) a year on tuition alone to study in the US. In previous years, Devatwal's organisation sent more than 100 students to American universities but this year he said the number had dropped to about 10. Instead, families were shifting their focus to the UK and other European countries. A recent analysis by the Hindu newspaper estimated a 28% drop in Indian students going to the US in 2025. 'Families contribute their savings, take out loans from banks and borrow from relatives, all in the hope that the student will secure a good job abroad, repay the debt, and build a promising future,' said Devatwal. 'In such uncertain circumstances, parents are understandably reluctant to let their children take such a risky path.' Brijesh Patel, 50, a textile trader in Surat, Gujarat, said he had been saving money for over a decade to make sure his son could go to a US university, including selling his wife's jewellery and borrowing money from relatives. 'Everyone in the family wanted our son to go to the US for his studies and make something good of his life,' said Patel. His 21-year-old son, who he asked not to be named for fear of retribution by the US authorities, had secured a place at two American universities for his master's degree and Patel had already paid 700,000 rupees (£6,000) to consultancies who helped with the applications. But amid the turmoil under Trump, Patel said his son was being advised not to even apply for his student visa, due to the uncertainty and high probability of rejection. 'We simply can't take that risk. If our son goes now and something goes wrong, we won't be able to save that kind of money again,' he said. However, Patel said he was not willing to give up on the family dream just yet. 'I am an optimist, and my son is willing to wait a year,' he said. 'We're hoping that things improve by then. It's not just my son who will be living the American dream, it's all of us: my wife, our relatives and our neighbours. I've struggled my whole life – I don't want my son to face the same struggles here in India.' The fear among prospective and current students was palpable. Several Indian students studying in the US declined to speak to the Guardian, fearing it could jeopardise their visas. In India, a student selected in December to be one of this year's Fulbright-Nehru doctoral fellows – a highly competitive scholarship that pays for the brightest students to study abroad at US universities as part of their PhD thesis – said the applications of their entire cohort had recently been demoted back to 'semi-finalists'. The student, who asked to remain anonymous over fears it would affect their application, said they had invitation letters from top Ivy League universities for the fellowship, which is considered one of the most prestigious scholarships in the US, but now everything was up in the air. 'We are supposed to start in October and our orientation was scheduled for May, all the flights and hotels were even booked, but then it all got cancelled. Now we've been informed all our applications are under review by the Trump administration,' said the student. They said it had caused 'huge panic and anxiety' among those accepted. 'I know a lot of people are going back through their social media, deleting things and doing a lot of self-censoring.' Piyush Bhartiya, a co-founder of the educational technology company AdmitKard, said many parents who had been set on sending their children to the US were rethinking their plans. He cited one example of a student who had been admitted to New York University for the coming year but was instead planning to go to the London School of Economics after the US visa interviews were paused. Bhartiya said Indian students primarily went to the US to study Stem subjects – science, technology, engineering and maths – and so the focus had shifted to other countries strong in these areas. 'Germany is the main country where students are shifting to for Stem subjects,' he said. 'Other countries like Ireland, France, the Netherlands, which are also gaining substantial interest in the students. At the undergraduate level, the Middle East has also seen a lot of gain in interest given parents feel that it is close by and safer and given the current political environment they may want their kids closer to the home.' Among the Indian students forced to abandon their plans is Nihar Gokhale, 36. He had a fully funded offer for a PhD at a private university in Massachusetts, but recently received a letter saying the funding was being withdrawn, as the university faced issues under the Trump administration. 'It was quite shocking. I spoke to people at the university, and they admitted it was an exceptional situation for them too,' said Gokhale. Without the funding, the US was financially 'out of the question' and he said he had an offer from the UK he now intended to take up. 'For at least the next three or four years, I'm not considering the US at all,' he said. • This article was amended on 4 June 2025 to correct a conversion error. An earlier version said that 700,000 rupees was £68,000 instead of saying £6,000.
